FDA, DOJ go after e-cigarette companies for breaking the law

E-cigarette manufacturers are under fire from the Department of Justice (DOJ), which is seeking a permanent injunction in federal district courts against six manufacturers. 

The DOJ is seeking the injunction on behalf of the Food and Drug Administration (FDA) after the agency already barred popular e-cigarette company Juul from marketing and selling and distributing its products earlier this year. The latest injunction from the DOJ would require the companies to stop manufacturing, selling, and distributing their e-cigarettes, as well as obtain marketing authorization from the FDA before marketing their products. 

The FDA and the DOJ targeted six companies in U.S. District courts, including:

  • Morin Enterprises Inc. doing business as E-Cig Crib in the District of Minnesota
  • Soul Vapor LLC in the Southern District of West Virginia
  • Super Vape’z LLC in the Western District of Washington
  • Vapor Craft LLC in the Middle District of Georgia
  • Lucky’s Convenience & Tobacco LLC doing business as Lucky’s Vape & Smoke Shop in the District of Kansas
  • Seditious Vapours LLC doing business as Butt Out in the District of Arizona

According to the FDA, the defendants have failed to submit premarket applications for their e-cigarettes and have continued to illegally manufacture, sell and distribute their products, even after being warned by the FDA they were breaking the law. Specifically, the companies violated the Federal Food, Drug and Cosmetic (FD&C) Act’s premarket review requirements for new tobacco products, according to the FDA. 

“Today’s enforcement actions represent a significant step for the FDA in preventing tobacco product manufacturers from violating the law,” Brian King, PhD, MPH, director of the FDA’s Center for Tobacco Products, said in a statement. “We will not stand by as manufacturers repeatedly break the law, especially after being afforded multiple opportunities to comply.” 

With the injunctions filed, the companies can agree to consent degrees to stop manufacturing, selling or distributing any new tobacco products unless and until certain prerequisites are met. This includes receiving authorization from the FDA to market the products, FDA inspections of facilities to determine compliance and notification from the FDA that the defendants are in compliance. If the companies don’t accept consent decrees, the government can enforce injunctions. 

“These cases are an important step in stopping the illegal sale of unauthorized electronic nicotine delivery system products,” Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division, said in a statement. “The Department of Justice will continue to work closely with FDA to stop the distribution of illegal, unauthorized tobacco products.” 

Between January 2021 through Sept. 9, 2022, the FDA issued nearly 300 warning letters, to firms that collectively have more than 17 million e-cigarettes listed with the agency, for failure to submit a timely premarket application, the FDA said, noting its first step is to issue a written letter in an attempt to receive voluntary compliance with the law. After receiving warnings, the majority of companies comply and remove their products from the market. 
 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”